SEARCH:   Advanced

Blood, 1 December 2008, Vol. 112, No. 12, pp. 4437-4444. Prepublished online as a Blood First Edition Paper on August 27, 2008; DOI 10.1182/blood-2008-06-162388. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-06-162388v1 blood-2008-06-162388v2 112/12/4437    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Marin, D. Articles by Apperley, J. F. Search for Related Content PubMed PubMed Citation Articles by Marin, D. Articles by Apperley, J. F. Related Collections Neoplasia Free Research Articles Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor David Marin1, Dragana Milojkovic1, Eduardo Olavarria1, Jamshid S. Khorashad1, Hugues de Lavallade1, Alistair G. Reid1, Letizia Foroni1, Katayoun Rezvani1, Marco Bua1, Francesco Dazzi1, Jiri Pavlu1, Matthias Klammer1, Jaspal S. Kaeda1, John M. Goldman1, and Jane F. Apperley1 1 Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, United Kingdom The majority of patients with chronic myeloid leukemia in chronic phase gain substantial benefit from imatinib but some fail to respond or lose their initial response. In 2006, the European LeukemiaNet published recommendations designed to help identify patients responding poorly to imatinib. Patients were evaluated at 3, 6, 12, and 18 months and some were classified as "failure" or "suboptimal responders." We analyzed outcomes for 224 patients with chronic myeloid leukemia in chronic phase treated in a single institution to validate these recommendations. Patients were followed for a median of 46.1 months. At each time point, patients classified as "failure" showed significantly worse survival, progression-free survival, and cytogenetic response than other patients; for example, based on the assessment at 12 months, the 5-year survival was 87.1% versus 95.1% (P = .02), progression-free survival 76.% versus 90% (P = .002), and complete cytogenetic response rate 26.7% versus 94.1% (P < .001). Similarly, the criteria for "suboptimal response" at 6 and 12 months identified patients destined to fare badly, although criteria at 18 months were less useful. The predictive value of some other individual criteria varied. In general, the LeukemiaNet criteria have useful predictive value, but a case could now be made for combining the categories "failure" and "suboptimal response." CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Jabbour, J. E. Cortes, and H. M. Kantarjian Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Mayo Clin. Proc., February 1, 2009; 84(2): 161 - 169. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020